A Biomarker-driven, Open Label, Single Arm, Multicentre Phase II Study of Abemaciclib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Who Failed to Platinum-based Therapy
Conditions: HNSCC; Head and Neck Neoplasms Intervention: Drug: Abemaciclib Sponsor: Seoul National University Hospital Recruiting
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου